| 2.64 -0.06 (-2.22%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.44 | 1-year : | 4.02 |
| Resists | First : | 2.95 | Second : | 3.44 |
| Pivot price | 2.55  |
|||
| Supports | First : | 2.36 | Second : | 2 |
| MAs | MA(5) : | 2.54 |
MA(20) : | 2.47 |
| MA(100) : | 2.78  |
MA(250) : | 7.55 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 48.1 |
D(3) : | 44.1 |
| RSI | RSI(14): 56.4 |
|||
| 52-week | High : | 24 | Low : | 1.78 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MBRX ] has closed below upper band by 33.7%. Bollinger Bands are 47.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.79 - 2.81 | 2.81 - 2.82 |
| Low: | 2.57 - 2.58 | 2.58 - 2.6 |
| Close: | 2.61 - 2.64 | 2.64 - 2.66 |
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
Fri, 05 Jun 2026
Strong physician interest in Annamycin reported by Moleculin (NASDAQ: MBRX) - Stock Titan
Fri, 05 Jun 2026
Leukemia drug Annamycin wins doctor and insurer support in new survey - Stock Titan
Thu, 04 Jun 2026
Leukemia trial of Annamycin hits 45-patient milestone, mid‑2026 data ahead - Stock Titan
Fri, 29 May 2026
Cancer trial tests Annamycin beyond chemo limits, finds no heart toxicity - Stock Titan
Tue, 26 May 2026
Moleculin Biotech (NASDAQ: MBRX) posts new May 2026 investor presentation - Stock Titan
Fri, 22 May 2026
Annamycin cardiac safety data at ASCO 2026 for Moleculin (NASDAQ: MBRX) - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 4.4 (%) |
| Shares Short | 528 (K) |
| Shares Short P.Month | 139 (K) |
| EPS | -16.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -76.2 % |
| Return on Equity (ttm) | -532.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.17 |
| PEG Ratio | 0 |
| Price to Book value | 0.56 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|